Ozempic Mounjaro GLP-1 Gastroparesis Lawsuit
Popular GLP-1 medications used for diabetes and weight loss may cause severe side effects which may result in hospitalization, permanent injury, or other serious complications. Serious adverse events and complications of these medications may include Gastroparesis (paralysis of the stomach), Ileus, Pancreatitis, Bowel obstruction (blocked intestine), and Pulmonary aspiration while under anesthesia or during surgery.
Medical professionals and the U.S. Food and Drug Administration have reported increased numbers of Emergency Room Visits and hospitalizations related to complications caused by GLP-1 medications.
Medications that have been linked to these serious disorders include:
Drugmakers Eli Lilly and Novo Nordisk may be facing numerous lawsuits filed by people who used the medications and experienced serious complications or required hospitalization. People who were hospitalized due to gastroparesis or bowel obstruction, who were diagnosed with ileus or pancreatitis, or who experienced pulmonary aspiration during surgery or while under anesthesia after using Ozempic, Wegovy, Saxenda, Victoza, or Mounjaro may be eligible for compensation.
GLP-1 Antidiabetic Medications
Glucagon-like Peptide-1 (GLP-1) agonists are injectable medications used to treat Type 2 diabetes and may also cause weight loss. GLP-1 medications work by delaying stomach emptying or slowing the intestines so that the person feels “full” for longer and appetite is reduced.
GLP-1 Medications include:
- Ozempic (semaglutide)
- Mounjaro (tirzepatide)
- Wegovy (semaglutide)
- Saxenda (liraglutide)
- Victoza (liraglutide
All GLP-1 agonist medications are approved for the treatment of Type 2 diabetes and to reduce the risk of cardiovascular events such as heart attack, stroke, and death in diabetics with heart disease. Though only Wegovy is also approved as a weight loss medication, other drugs have been used “off-label” for weight loss.
Serious Complications of Ozempic, Wegovy, Mounjaro and other GLP-1 Medications
GLP-1 medications such as Ozempic, Wegovy, Mounjaro and others, have been linked to serious gastrointestinal illnesses and serious complications which may result in hospitalization or permanent injury. The Food and Drug Administration has received hundreds of adverse event reports linked to the drugs.
Side effects and complications may include:
- Gastroparesis (paralysis of the stomach), requiring hospitalization;
- Bowel obstruction (blocked intestine), requiring hospitalization;
- Pancreatitis; and
- Pulmonary aspiration while under anesthesia or during surgery
People who took GLP-1 medications like Ozempic, Wegovy, Saxenda, Victoza, or Mounjaro and experienced serious side effects may be eligible for compensation.
Ozempic, Mounjaro and Other Drugs Popular for Weight Loss
Novo Nordisk research published in a popular medical journal “The Lancet” shows that the active ingredient in Ozempic may help a person lose about 15% of their body weight. Similar effectiveness has been shown by other medications including one recent study published in JAMA which showed a 5 to 20% weight loss.
Only Wegovy has been approved for the treatment of obesity but other GLP-1 medications like Ozempic, Mounjaro, Saxenda and Victoza have been used as “off-label” weight loss treatments. Though off-label use is allowed by the FDA, the medications have not been approved for these treatments and manufacturers may not promote or market the drugs for off-label treatments.
Many celebrities have said they are using Ozempic and other drugs to “drop 10 pounds” or “get skinny” and the medications have been the subject of discussion on celebrity talk shows and events. The medications have become so popular for weight loss that recent shortages have been announced.
Manufacturers Facing Ozempic, Mounjaro, Wegovy GLP-1 Lawsuits
Drugmakers Novo Nordisk, Eli Lilly and other manufacturers may be facing numerous lawsuits filed by people who developed severe complications after taking their GLP-1 medications
Filed lawsuits allege that the manufacturers knew or should have known about their medication’s links to serious gastrointestinal disorders and have been accused of downplaying adverse events and failing to adequately warn doctors and patients of the dangers of their medications.
People who used GLP-1 medications including Ozempic, Wegovy, Saxenda, Victoza or Mounjaro and
- Were diagnosed with Ileus or Pancreatitis,
- Required hospitalization for Gastroparesis or blocked intestine or
- Experienced Pulmonary aspiration during surgery
may be eligible for compensation.